GB Patent

GB9410222D0 — Medicaments

Assigned to Glaxo Wellcome Australia Ltd · Expires 1994-07-06 · 32y expired

What this patent protects

PCT No. PCT/EP95/01913 Sec. 371 Date Feb. 7, 1997 Sec. 102(e) Date Feb. 7, 1997 PCT Filed May 19, 1995 PCT Pub. No. WO95/31964 PCT Pub. Date Nov. 30, 1995Suspension formulations suitable for nebulization, for administration by inhalation, comprising fluticasone propionate with a …

USPTO Abstract

PCT No. PCT/EP95/01913 Sec. 371 Date Feb. 7, 1997 Sec. 102(e) Date Feb. 7, 1997 PCT Filed May 19, 1995 PCT Pub. No. WO95/31964 PCT Pub. Date Nov. 30, 1995Suspension formulations suitable for nebulization, for administration by inhalation, comprising fluticasone propionate with a particle size less than 12 microns, one or more surfactants, one or more buffer agents and water. Also described are a method of preparing such a formulation, a container comprising the formulation, and a method of treating asthma using the formulation.

Drugs covered by this patent

Patent Metadata

Patent number
GB9410222D0
Jurisdiction
GB
Classification
—
Expires
1994-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Wellcome Australia Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.